Enoxacin

12 interactions on record

Enoxacin has 12 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 6 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Duloxetine, Pirfenidone, Clozapine. Patients taking Enoxacin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 12
Contraindicated: 2
Major: 6
Moderate: 4

Contraindicated (2)

Enoxacin + Duloxetine— Quinolone antimicrobial that inhibits CYP1A2; should be avoided due to significant increase in duloxetine concentrations…
Enoxacin + Pirfenidone— Strong CYP1A2 inhibitor that significantly increases pirfenidone exposure. Should be discontinued prior to pirfenidone a…

Major (6)

Enoxacin + Clozapine— Strong CYP1A2 inhibitor that increases clozapine plasma levels, potentially resulting in adverse reactions. Requires dos…
Enoxacin + Duloxetine Hydrochloride— Quinolone antimicrobial and potent CYP1A2 inhibitor that should be avoided due to potential significant increase in dulo…
Enoxacin + Pirfenidone Capsule, 267 Mg— Strong CYP1A2 inhibitor that significantly increases pirfenidone exposure. Should be discontinued prior to pirfenidone a…
Enoxacin + Roflumilast— CYP3A4 and CYP1A2 inhibitor that increases roflumilast systemic exposure and may result in increased adverse reactions.
Enoxacin + Warfarin— CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring
Enoxacin + Warfarin Sodium— CYP1A2 inhibitor that increases warfarin effect and INR; requires closer INR monitoring.

Moderate (4)

Enoxacin + Asenapine— Strong CYP1A2 inhibitor that increases asenapine AUC and Cmax. Consider asenapine dose reduction based on clinical respo…
Enoxacin + Duloxetine D/R— Quinolone antimicrobial that inhibits CYP1A2 and may increase duloxetine concentrations.
Enoxacin + Propranolol Hydrochloride— CYP1A2 inhibitor that increases propranolol exposure. Monitor for bradycardia and hypotension.
Enoxacin + Riluzole— CYP1A2 inhibitor that may increase riluzole exposure and risk of riluzole-associated adverse reactions.

Enoxacin + Duloxetine⛔Contraindicated

Quinolone antimicrobial that inhibits CYP1A2; should be avoided due to significant increase in duloxetine concentrations.

Enoxacin + Pirfenidone⛔Contraindicated

Strong CYP1A2 inhibitor that significantly increases pirfenidone exposure. Should be discontinued prior to pirfenidone administration and avoided during treatment.

Enoxacin + Clozapine⚠️Major

Strong CYP1A2 inhibitor that increases clozapine plasma levels, potentially resulting in adverse reactions. Requires dose reduction to one-third.

Enoxacin + Duloxetine Hydrochloride⚠️Major

Quinolone antimicrobial and potent CYP1A2 inhibitor that should be avoided due to potential significant increase in duloxetine concentrations.

Enoxacin + Pirfenidone Capsule, 267 Mg⚠️Major

Strong CYP1A2 inhibitor that significantly increases pirfenidone exposure. Should be discontinued prior to pirfenidone administration and avoided during treatment.

Enoxacin + Roflumilast⚠️Major

CYP3A4 and CYP1A2 inhibitor that increases roflumilast systemic exposure and may result in increased adverse reactions.

Enoxacin + Warfarin⚠️Major

CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring

Enoxacin + Warfarin Sodium⚠️Major

CYP1A2 inhibitor that increases warfarin effect and INR; requires closer INR monitoring.

Enoxacin + Asenapine🟡Moderate

Strong CYP1A2 inhibitor that increases asenapine AUC and Cmax. Consider asenapine dose reduction based on clinical response.

Enoxacin + Duloxetine D/R🟡Moderate

Quinolone antimicrobial that inhibits CYP1A2 and may increase duloxetine concentrations.

Enoxacin + Propranolol Hydrochloride🟡Moderate

CYP1A2 inhibitor that increases propranolol exposure. Monitor for bradycardia and hypotension.

Enoxacin + Riluzole🟡Moderate

CYP1A2 inhibitor that may increase riluzole exposure and risk of riluzole-associated adverse reactions.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.